Catalog No.
DHB94410
Expression system
Mammalian Cells
Species reactivity
Human
Isotype
Fusion - [TNFRSF1A (tumor necrosis factor receptor (TNFR) superfamilly member 1A, TNFAR, TNF-RI, TNF-R-I, p55, CD120a)]2 - IGHG1 Fc (Fragment constant)
Target
TNF, Tumor necrosis factor ligand superfamily member 2, N-terminal fragment, ICD2, NTF, TNF-a, TNF-alpha, Tumor necrosis factor, TNFSF2, TNFA, Cachectin, ICD1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01375
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
TNFR55-Ig1,TNFRSF1A-Fc,p55TNF-R:Ig, CAS: 156679-34-4
Clone ID
Lenercept
Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein., PMID:22714051
Potential errors in the volume of distribution estimation of therapeutic proteins composed of differently cleared components., PMID:21779940
Tumour Necrosis Factor Neutralization in MS: A Cautionary Tale., PMID:21689500
Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein., PMID:20100527
Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier., PMID:19624167
A novel paradigm for dendritic cells as effectors of cartilage destruction., PMID:19269957
Biological agents in rheumatoid arthritis: which ones could be used in combination?, PMID:18020567
Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content., PMID:17728143
Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent., PMID:17363402
Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys., PMID:17331977
Adalimumab-associated multiple sclerosis., PMID:17216704
Antitumor-associated antigens IgGs: dual positive and negative potential effects for cancer therapy., PMID:17163176
The role of TNF in hepatic histopathological manifestations and hepatic CD8+ T cell alloresponses in murine MHC class I disparate GVHD., PMID:16081594
Focus on: biologics that affect therapeutic agents in dermatology., PMID:15776786
Use of porcine tumor necrosis factor receptor 1-Ig fusion protein to prolong xenograft survival., PMID:15479458
Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis., PMID:15197059
The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview., PMID:15013927
Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation., PMID:14691170
Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis., PMID:14599631
Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis., PMID:14528504
Gateways to clinical trials., PMID:12851663
Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis., PMID:12799209
Tumor necrosis factor inhibitor gene expression suppresses lacrimal gland immunopathology in a rabbit model of autoimmune dacryoadenitis., PMID:12792478
Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis., PMID:12672184
Effect of anti-inflammatory cytokines on the activation of lymphocytes by lacrimal gland acinar cells in an autologous mixed cell reaction., PMID:12613993
Targeting of macrophage activity by adenovirus-mediated intragraft overexpression of TNFRp55-Ig, IL-12p40, and vIL-10 ameliorates adenovirus-mediated chronic graft injury, whereas stimulation of macrophages by overexpression of IFN-gamma accelerates chronic graft injury in a rat renal allograft model., PMID:12506154
Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects., PMID:12412939
Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials., PMID:12102646
Expression of IL-10 and TNF-inhibitor genes in lacrimal gland epithelial cells suppresses their ability to activate lymphocytes., PMID:11862098
Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues., PMID:11467948
Importance of underlying mechanism and genotype on outcome of sepsis trials., PMID:11373447
Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients., PMID:11373411
Isolated digital vasculitis in a patient with rheumatoid arthritis: good response to tumour necrosis factor alpha blocking treatment., PMID:11302883
Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?, PMID:11244034
[Value of anti-TNF-alpha molecules in inflammatory and infectious diseases]., PMID:11075396
Enhancement of MHC class I-stimulated alloresponses by TNF/TNF receptor (TNFR)1 interactions and of MHC class II-stimulated alloresponses by TNF/TNFR2 interactions., PMID:11069072
[Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment]., PMID:10996910
Ammonium alters N-glycan structures of recombinant TNFR-IgG: degradative versus biosynthetic mechanisms., PMID:10799988
[Role of anti-TNF therapy in rheumatoid arthritis]., PMID:10745935
No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients., PMID:10720082
Secretion of glycosylation site mutants can be rescued by the signal/pro sequence of tissue plasminogen activator., PMID:10536368
Impact of immunomodulating therapy on morbidity in patients with severe sepsis., PMID:10471608
TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group., PMID:10449104
National Meeting of the American College of Rheumatology. November 8-12, 1998, San Diego, California., PMID:10340106
TNF-alpha-targeted therapy in rheumatoid arthritis., PMID:10339773
[62nd Congress of the American College of Rheumatology, San Diego, 8-12 November 1998]., PMID:10327473
Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans., PMID:9884305
Biological insights from clinical trials with anti-TNF therapy., PMID:9836378
USAN Council. List No.407. New names. Lenercept., PMID:9758530
Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways., PMID:9426830
For research use only. Not for human or drug use.
